Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Neuroblastoma 2Ganglioneuroblastoma 2

Interventions

Temozolomide 31Magnetic Resonance Spectroscopy 31Specimen Handling 18Radiation 13Radiotherapy 12Biopsy 11Bevacizumab 11Nivolumab 9X-Rays 7Radiosurgery 7Nuclear Medicine Department, Hospital 7Carboplatin 7Lomustine 6Cyclophosphamide 6Vincristine 5Phantoms, Imaging 5Cisplatin 5ulixertinib 4trametinib 4pembrolizumab 4erdafitinib 4binimetinib 4abemaciclib 4Irinotecan 4Ipilimumab 4Immunoglobulin G 4Etoposide 4Disulfides 4Aminolevulinic Acid 4AZD 6244 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
dinutuximab × CNS × 30 days × Clear all
NCT07318831 2026-06-04

Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
27 enrolled
CNS

Neuroblastoma

NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡